{"doc_id": "33790308", "type of study": "Therapy", "title": "", "abstract": "Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.\nFavipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections.\nWe aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases.\nIt was randomized-controlled open-label interventional phase 3 clinical trial [NCT04349241].\n100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir 3200\u00a0mg at day 1 followed by 600\u00a0mg twice (day 2-day 10).\n50 patients received hydroxychloroquine 800\u00a0mg at day 1 followed by 200\u00a0mg twice (day 2-10) and oral oseltamivir 75\u00a0mg/12\u00a0h/day for 10\u00a0days.\nPatients were enrolled from Ain Shams University Hospital and Assiut University Hospital.\nBoth arms were comparable as regards demographic characteristics and comorbidities.\nThe average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3\u00a0days in HCQ-arm and favipiravir-arm respectively.\n55.1% of those on HCQ-arm turned PCR negative at/or before 7th day from diagnosis compared to 48% in favipiravir-arm (p\u2009=\u20090.7).\n4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm.\nOnly one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure.\nFavipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients.\n", "Evidence Map": {"Enrollment": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 86}, {"term": "COVID-19 mild and moderate", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 101}, {"term": "mild or moderate COVID-19 infected", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 104}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19 : A randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 86}], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 34, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 60, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases .", "Evidence Elements": {"Participant": [{"term": "COVID-19 mild and moderate", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 101}], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 58, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 30}, {"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 43}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "It was randomized-controlled open-label interventional phase 3 clinical trial [ NCT04349241 ] .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "100 patients were recruited from 18th April till 18th May . 50 patients received favipiravir 3200 mg at day 1 followed by 600 mg twice ( day 2-day 10 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "favipiravir", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 92, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "50 patients received hydroxychloroquine 800 mg at day 1 followed by 200 mg twice ( day 2-10 ) and oral oseltamivir 75 mg / 12 h / day for 10 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 39, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}, {"term": "oral oseltamivir", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 114, "has_chemical": [{"text": "oseltamivir", "maps_to": "C0874161:oseltamivir", "start": 5, "end": 16, "has_route": ["oral"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Patients were enrolled from Ain Shams University Hospital and Assiut University Hospital .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Both arms were comparable as regards demographic characteristics and comorbidities .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The average onset of SARS-CoV-2 PCR negativity was 8.1 and 8.3 days in HCQ-arm and favipiravir-arm respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HCQ-arm", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 78, "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "favipiravir-arm", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 98, "has_procedure": [{"text": "favipiravir arm", "maps_to": "C1522541:arm", "start": 0, "end": 15}], "has_relation": "N/A"}], "Outcome": [{"term": "average onset of SARS-CoV-2 PCR negativity", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 46}], "Observation": [{"term": "8.1", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 54}, {"term": "8.3 days", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 67}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "HCQ-arm", "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "8.1", "Outcome": "average onset of SARS-CoV-2 PCR negativity", "Count": ""}, {"Intervention": {"term": "favipiravir-arm", "has_procedure": [{"text": "favipiravir arm", "maps_to": "C1522541:arm", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "8.3 days", "Outcome": "average onset of SARS-CoV-2 PCR negativity", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "55.1 % of those on HCQ-arm turned PCR negative at / or before 7th day from diagnosis compared to 48 % in favipiravir-arm ( p = 0.7 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HCQ-arm", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 26, "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "favipiravir-arm", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 120, "has_procedure": [{"text": "favipiravir arm", "maps_to": "C1522541:arm", "start": 0, "end": 15}], "has_relation": "N/A"}], "Outcome": [{"term": "PCR negative", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 46}], "Observation": [], "Count": [{"term": "55.1 %", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}, {"term": "48 %", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 101}]}, "Evidence Propositions": [{"Intervention": {"term": "HCQ-arm", "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "", "Count": "55.1 %", "Outcome": "PCR negative"}, {"Intervention": {"term": "favipiravir-arm", "has_procedure": [{"text": "favipiravir arm", "maps_to": "C1522541:arm", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "", "Count": "48 %", "Outcome": "PCR negative"}]}, {"Section": "UNKNOWN", "Text": "4 patients in FVP arm developed transient transaminitis on the other hand heartburn and nausea were reported in about 20 patients in HCQ-arm .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "FVP", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 17, "has_relation": "N/A"}, {"term": "HCQ-arm", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 140, "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "transient transaminitis", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 55}, {"term": "heartburn", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 83}, {"term": "nausea", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 94}], "Observation": [], "Count": [{"term": "4 patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 10}, {"term": "20 patients", "negation": "affirmed", "UMLS": {}, "start": 118, "end": 129}]}, "Evidence Propositions": [{"Intervention": {"term": "FVP", "has_relation": "N/A"}, "Observation": "", "Count": "4 patients", "Outcome": "transient transaminitis"}, {"Intervention": {"term": "HCQ-arm", "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "", "Count": "20 patients", "Outcome": "nausea"}]}, {"Section": "UNKNOWN", "Text": "Only one patient in HCQ-arm died after developing acute myocarditis resulted in acute heart failure .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "HCQ-arm", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 27, "has_procedure": [{"text": "hcq arm", "maps_to": "C1522541:arm", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "died", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 32}, {"term": "acute myocarditis", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 67}, {"term": "acute heart failure", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 99}], "Observation": [], "Count": [{"term": "one patient", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 16}]}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Favipiravir is a safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients .", "Evidence Elements": {"Participant": [{"term": "mild or moderate COVID-19 infected", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 104}], "Intervention": [{"term": "Favipiravir", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11, "has_chemical": [{"text": "favipiravir", "maps_to": "C1138226:favipiravir", "start": 0, "end": 11}], "has_relation": "N/A"}, {"term": "hydroxychloroquine", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 66, "has_chemical": [{"text": "hydroxychloroquine", "maps_to": "C0020336:hydroxychloroquine", "start": 0, "end": 18}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "safe effective", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 31}], "Count": []}, "Evidence Propositions": []}]}